We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

59 hedge funds and large institutions have $32.9M invested in Akoya BioSciences in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

24% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 17

13% more capital invested

Capital invested by funds: $29M → $32.9M (+$3.91M)

0% more funds holding

Funds holding: 5959 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

0.65% less ownership

Funds ownership: 25.08%24.43% (-0.65%)

Holders
59
Holders Change
Holders Change %
0%
% of All Funds
0.85%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
7
Increased
21
Reduced
17
Closed
7
Calls
$104K
Puts
Net Calls
+$104K
Net Calls Change
-$76K
Name Holding Trade Value Shares
Change
Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
$12.8M
BlackRock
2
BlackRock
New York
$4.3M +$191K +78,277 +5%
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.04M +$51.6K +21,120 +1%
PAPAIJV
4
Paragon Associates & Paragon Associates II Joint Venture
Texas
$2.15M +$1.07M +440,000 +126%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.53M -$1.25K -514 -0.1%
State Street
6
State Street
Massachusetts
$1.23M +$44.8K +18,361 +4%
PHP
7
Parkman Healthcare Partners
Connecticut
$1.02M +$1.45K +595 +0.2%
GCP
8
GSA Capital Partners
United Kingdom
$845K +$354K +144,903 +87%
SSA
9
Schonfeld Strategic Advisors
New York
$738K -$56K -22,942 -8%
PCA
10
Peddock Capital Advisors
Massachusetts
$638K -$503 -206 -0.1%
Northern Trust
11
Northern Trust
Illinois
$573K +$2.02K +827 +0.4%
Morgan Stanley
12
Morgan Stanley
New York
$464K +$152K +62,227 +58%
OCM
13
Osterweis Capital Management
California
$343K
BCM
14
Bridgeway Capital Management
Texas
$287K -$181K -74,000 -41%
Charles Schwab
15
Charles Schwab
California
$171K -$276K -112,886 -64%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$153K -$27.1K -11,086 -16%
Goldman Sachs
17
Goldman Sachs
New York
$144K +$96.6K +39,563 +297%
Citadel Advisors
18
Citadel Advisors
Florida
$141K +$108K +44,026 +566%
ZIC
19
ZWJ Investment Counsel
Georgia
$123K -$2.93K -1,200 -3%
N
20
Nuveen
North Carolina
$111K
Barclays
21
Barclays
United Kingdom
$107K +$73.5K +30,095 +321%
AllianceBernstein
22
AllianceBernstein
Tennessee
$89.9K
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$82.8K +$4.22K +1,729 +6%
Jane Street
24
Jane Street
New York
$82.7K -$34.9K -14,288 -32%
TCA
25
Transcend Capital Advisors
New Jersey
$75.1K +$67.4K +27,600 New

AKYA Hedge Fund Activity: Q3 2024 in Review

59 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q3 2024, worth a combined $32.9M — up 13% from $29M a quarter earlier.

Fund positioning in AKYA was balanced in Q3 2024: 7 funds opened new positions, 7 closed out, 21 added to existing stakes and 17 trimmed.

The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, adding an estimated $1.07M. The largest seller was SVB Wealth, exiting entirely with an estimated $1.21M sold.

  • 59 institutional investors held Akoya BioSciences (AKYA) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $32.9M of Akoya BioSciences stock for Q3 2024, up 13% quarter-over-quarter.
  • 7 funds opened new Akoya BioSciences positions in Q3 2024 and 7 closed out, a net change of 0 holders.
  • The largest Akoya BioSciences buyer in Q3 2024 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $1.07M added.
  • The largest Akoya BioSciences seller in Q3 2024 was SVB Wealth, an estimated $1.21M sold.

Based on aggregated 13F filings for Q3 2024.